Revance Announces Departure of Chief Financial Officer
Following Ms. Silvernail's resignation, certain members of management and the Company's existing finance team will assume the duties and responsibilities of the office on an interim basis.
Revance is initiating a search for its next Chief Financial Officer, who will play an important role as the Company prepares for the commercialization of its lead product candidate, DaxibotulinumtoxinA for Injection (RT002).
Nadine Tosk, 504-453-8344
News Provided by Acquire Media